

Urological Cancer Therapeutics Drugs Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/UA7249E3D025EN.html>

Date: March 2022

Pages: 114

Price: US\$ 3,250.00 (Single User License)

ID: UA7249E3D025EN

Abstracts

Global Urological Cancer Therapeutics Drugs Market is estimated to reach \$48.6 billion by 2025 Says, .Now a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs.

This report contains market size and forecasts of Urological Cancer Therapeutics Drugs in global, including the following market information:

Global Urological Cancer Therapeutics Drugs Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global Urological Cancer Therapeutics Drugs Market Sales, 2017-2022, 2023-2028, (K MT)

Global top five Urological Cancer Therapeutics Drugs companies in 2021 (%)

The global Urological Cancer Therapeutics Drugs market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Xofigo (radium Ra 223 dichloride) Segment to Reach \$ Million by 2028, with a % CAGR

in next six years.

The global key manufacturers of Urological Cancer Therapeutics Drugs include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Urological Cancer Therapeutics Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Urological Cancer Therapeutics Drugs Market, by Type, 2017-2022, 2023-2028
(\$ Millions) & (K MT)

Global Urological Cancer Therapeutics Drugs Market Segment Percentages, by Type, 2021 (%)

Xofigo (radium Ra 223 dichloride)

Jevtana (cabazitaxel)

Inlyta (axitinib)

Votrient (pazopanib hydrochloride)

Sutent (sunitinib malate)

Zytiga (abiraterone acetate)

Xtandi (enzalutamide)

Opdivo (nivolumab)

Provenge (sipuleucel-T)

Global Urological Cancer Therapeutics Drugs Market, by Application, 2017-2022,
2023-2028 (\$ Millions) & (K MT)

Global Urological Cancer Therapeutics Drugs Market Segment Percentages, by
Application, 2021 (%)

Hospital

Medical Research Laboratory

Others

Global Urological Cancer Therapeutics Drugs Market, By Region and Country,
2017-2022, 2023-2028 (\$ Millions) & (K MT)

Global Urological Cancer Therapeutics Drugs Market Segment Percentages, By Region
and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Urological Cancer Therapeutics Drugs revenues in global market, 2017-2022 (Estimated), (\$ millions)

Key companies Urological Cancer Therapeutics Drugs revenues share in global market, 2021 (%)

Key companies Urological Cancer Therapeutics Drugs sales in global market, 2017-2022 (Estimated), (K MT)

Key companies Urological Cancer Therapeutics Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline plc

Indevus Pharmaceuticals Inc

Ipsen

Roche Healthcare

Sanofi S.A.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Urological Cancer Therapeutics Drugs Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Urological Cancer Therapeutics Drugs Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL UROLOGICAL CANCER THERAPEUTICS DRUGS OVERALL MARKET SIZE

- 2.1 Global Urological Cancer Therapeutics Drugs Market Size: 2021 VS 2028
- 2.2 Global Urological Cancer Therapeutics Drugs Revenue, Prospects & Forecasts: 2017-2028
- 2.3 Global Urological Cancer Therapeutics Drugs Sales: 2017-2028

3 COMPANY LANDSCAPE

- 3.1 Top Urological Cancer Therapeutics Drugs Players in Global Market
- 3.2 Top Global Urological Cancer Therapeutics Drugs Companies Ranked by Revenue
- 3.3 Global Urological Cancer Therapeutics Drugs Revenue by Companies
- 3.4 Global Urological Cancer Therapeutics Drugs Sales by Companies
- 3.5 Global Urological Cancer Therapeutics Drugs Price by Manufacturer (2017-2022)
- 3.6 Top 3 and Top 5 Urological Cancer Therapeutics Drugs Companies in Global Market, by Revenue in 2021
- 3.7 Global Manufacturers Urological Cancer Therapeutics Drugs Product Type
- 3.8 Tier 1, Tier 2 and Tier 3 Urological Cancer Therapeutics Drugs Players in Global Market
 - 3.8.1 List of Global Tier 1 Urological Cancer Therapeutics Drugs Companies
 - 3.8.2 List of Global Tier 2 and Tier 3 Urological Cancer Therapeutics Drugs Companies

4 SIGHTS BY PRODUCT

4.1 Overview

4.1.1 By Type - Global Urological Cancer Therapeutics Drugs Market Size Markets, 2021 & 2028

4.1.2 Xofigo (radium Ra 223 dichloride)

4.1.3 Jevtana (cabazitaxel)

4.1.4 Inlyta (axitinib)

4.1.5 Votrient (pazopanib hydrochloride)

4.1.6 Sutent (sunitinib malate)

4.1.7 Zytiga (abiraterone acetate)

4.1.8 Xtandi (enzalutamide)

4.1.9 Opdivo (nivolumab)

4.1.10 Provenge (sipuleucel-T)

4.2 By Type - Global Urological Cancer Therapeutics Drugs Revenue & Forecasts

4.2.1 By Type - Global Urological Cancer Therapeutics Drugs Revenue, 2017-2022

4.2.2 By Type - Global Urological Cancer Therapeutics Drugs Revenue, 2023-2028

4.2.3 By Type - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028

4.3 By Type - Global Urological Cancer Therapeutics Drugs Sales & Forecasts

4.3.1 By Type - Global Urological Cancer Therapeutics Drugs Sales, 2017-2022

4.3.2 By Type - Global Urological Cancer Therapeutics Drugs Sales, 2023-2028

4.3.3 By Type - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028

4.4 By Type - Global Urological Cancer Therapeutics Drugs Price (Manufacturers Selling Prices), 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Urological Cancer Therapeutics Drugs Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Medical Research Laboratory

5.1.4 Others

5.2 By Application - Global Urological Cancer Therapeutics Drugs Revenue & Forecasts

5.2.1 By Application - Global Urological Cancer Therapeutics Drugs Revenue, 2017-2022

5.2.2 By Application - Global Urological Cancer Therapeutics Drugs Revenue, 2023-2028

5.2.3 By Application - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028

5.3 By Application - Global Urological Cancer Therapeutics Drugs Sales & Forecasts

5.3.1 By Application - Global Urological Cancer Therapeutics Drugs Sales, 2017-2022

5.3.2 By Application - Global Urological Cancer Therapeutics Drugs Sales, 2023-2028

5.3.3 By Application - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028

5.4 By Application - Global Urological Cancer Therapeutics Drugs Price (Manufacturers Selling Prices), 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Urological Cancer Therapeutics Drugs Market Size, 2021 & 2028

6.2 By Region - Global Urological Cancer Therapeutics Drugs Revenue & Forecasts

6.2.1 By Region - Global Urological Cancer Therapeutics Drugs Revenue, 2017-2022

6.2.2 By Region - Global Urological Cancer Therapeutics Drugs Revenue, 2023-2028

6.2.3 By Region - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028

6.3 By Region - Global Urological Cancer Therapeutics Drugs Sales & Forecasts

6.3.1 By Region - Global Urological Cancer Therapeutics Drugs Sales, 2017-2022

6.3.2 By Region - Global Urological Cancer Therapeutics Drugs Sales, 2023-2028

6.3.3 By Region - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028

6.4 North America

6.4.1 By Country - North America Urological Cancer Therapeutics Drugs Revenue, 2017-2028

6.4.2 By Country - North America Urological Cancer Therapeutics Drugs Sales, 2017-2028

6.4.3 US Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.4.4 Canada Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.4.5 Mexico Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.5 Europe

6.5.1 By Country - Europe Urological Cancer Therapeutics Drugs Revenue, 2017-2028

6.5.2 By Country - Europe Urological Cancer Therapeutics Drugs Sales, 2017-2028

6.5.3 Germany Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.5.4 France Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.5.5 U.K. Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.5.6 Italy Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.5.7 Russia Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.5.8 Nordic Countries Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.5.9 Benelux Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.6 Asia

6.6.1 By Region - Asia Urological Cancer Therapeutics Drugs Revenue, 2017-2028

6.6.2 By Region - Asia Urological Cancer Therapeutics Drugs Sales, 2017-2028

6.6.3 China Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.6.4 Japan Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.6.5 South Korea Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.6.6 Southeast Asia Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.6.7 India Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.7 South America

6.7.1 By Country - South America Urological Cancer Therapeutics Drugs Revenue, 2017-2028

6.7.2 By Country - South America Urological Cancer Therapeutics Drugs Sales, 2017-2028

6.7.3 Brazil Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.7.4 Argentina Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.8 Middle East & Africa

6.8.1 By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Revenue, 2017-2028

6.8.2 By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Sales, 2017-2028

6.8.3 Turkey Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.8.4 Israel Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.8.5 Saudi Arabia Urological Cancer Therapeutics Drugs Market Size, 2017-2028

6.8.6 UAE Urological Cancer Therapeutics Drugs Market Size, 2017-2028

7 MANUFACTURERS & BRANDS PROFILES

7.1 Novartis

7.1.1 Novartis Corporate Summary

7.1.2 Novartis Business Overview

7.1.3 Novartis Urological Cancer Therapeutics Drugs Major Product Offerings

7.1.4 Novartis Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)

7.1.5 Novartis Key News

7.2 Pfizer

7.2.1 Pfizer Corporate Summary

7.2.2 Pfizer Business Overview

7.2.3 Pfizer Urological Cancer Therapeutics Drugs Major Product Offerings

7.2.4 Pfizer Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)

7.2.5 Pfizer Key News

7.3 Johnson & Johnson

7.3.1 Johnson & Johnson Corporate Summary

7.3.2 Johnson & Johnson Business Overview

7.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Major Product Offerings

7.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)

7.3.5 Johnson & Johnson Key News

7.4 AstraZeneca

7.4.1 AstraZeneca Corporate Summary

7.4.2 AstraZeneca Business Overview

7.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Major Product Offerings

7.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)

7.4.5 AstraZeneca Key News

7.5 Astellas

7.5.1 Astellas Corporate Summary

7.5.2 Astellas Business Overview

7.5.3 Astellas Urological Cancer Therapeutics Drugs Major Product Offerings

7.5.4 Astellas Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)

7.5.5 Astellas Key News

7.6 Bristol-Myers Squibb

7.6.1 Bristol-Myers Squibb Corporate Summary

7.6.2 Bristol-Myers Squibb Business Overview

7.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Major Product Offerings

7.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)

7.6.5 Bristol-Myers Squibb Key News

7.7 Abbott Laboratories

7.7.1 Abbott Laboratories Corporate Summary

- 7.7.2 Abbott Laboratories Business Overview
- 7.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Major Product Offerings
- 7.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
- 7.7.5 Abbott Laboratories Key News
- 7.8 Celgene Corporation
 - 7.8.1 Celgene Corporation Corporate Summary
 - 7.8.2 Celgene Corporation Business Overview
 - 7.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Major Product Offerings
 - 7.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
 - 7.8.5 Celgene Corporation Key News
- 7.9 Dendreon Corporation
 - 7.9.1 Dendreon Corporation Corporate Summary
 - 7.9.2 Dendreon Corporation Business Overview
 - 7.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Major Product Offerings
 - 7.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
 - 7.9.5 Dendreon Corporation Key News
- 7.10 Ferring Pharmaceuticals
 - 7.10.1 Ferring Pharmaceuticals Corporate Summary
 - 7.10.2 Ferring Pharmaceuticals Business Overview
 - 7.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Major Product Offerings
 - 7.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
 - 7.10.5 Ferring Pharmaceuticals Key News
- 7.11 GlaxoSmithKline plc
 - 7.11.1 GlaxoSmithKline plc Corporate Summary
 - 7.11.2 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Business Overview
 - 7.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Major Product Offerings
 - 7.11.4 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
 - 7.11.5 GlaxoSmithKline plc Key News
- 7.12 Indevus Pharmaceuticals Inc

- 7.12.1 Indevus Pharmaceuticals Inc Corporate Summary
- 7.12.2 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Business Overview
- 7.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Major Product Offerings
- 7.12.4 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
- 7.12.5 Indevus Pharmaceuticals Inc Key News
- 7.13 Ipsen
 - 7.13.1 Ipsen Corporate Summary
 - 7.13.2 Ipsen Urological Cancer Therapeutics Drugs Business Overview
 - 7.13.3 Ipsen Urological Cancer Therapeutics Drugs Major Product Offerings
 - 7.13.4 Ipsen Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
 - 7.13.5 Ipsen Key News
- 7.14 Roche Healthcare
 - 7.14.1 Roche Healthcare Corporate Summary
 - 7.14.2 Roche Healthcare Business Overview
 - 7.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Major Product Offerings
 - 7.14.4 Roche Healthcare Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
 - 7.14.5 Roche Healthcare Key News
- 7.15 Sanofi S.A.
 - 7.15.1 Sanofi S.A. Corporate Summary
 - 7.15.2 Sanofi S.A. Business Overview
 - 7.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Major Product Offerings
 - 7.15.4 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
 - 7.15.5 Sanofi S.A. Key News

8 GLOBAL UROLOGICAL CANCER THERAPEUTICS DRUGS PRODUCTION CAPACITY, ANALYSIS

- 8.1 Global Urological Cancer Therapeutics Drugs Production Capacity, 2017-2028
- 8.2 Urological Cancer Therapeutics Drugs Production Capacity of Key Manufacturers in Global Market
- 8.3 Global Urological Cancer Therapeutics Drugs Production by Region

9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

9.1 Market Opportunities & Trends

9.2 Market Drivers

9.3 Market Restraints

10 UROLOGICAL CANCER THERAPEUTICS DRUGS SUPPLY CHAIN ANALYSIS

10.1 Urological Cancer Therapeutics Drugs Industry Value Chain

10.2 Urological Cancer Therapeutics Drugs Upstream Market

10.3 Urological Cancer Therapeutics Drugs Downstream and Clients

10.4 Marketing Channels Analysis

10.4.1 Marketing Channels

10.4.2 Urological Cancer Therapeutics Drugs Distributors and Sales Agents in Global

11 CONCLUSION

12 APPENDIX

12.1 Note

12.2 Examples of Clients

12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Urological Cancer Therapeutics Drugs in Global Market

Table 2. Top Urological Cancer Therapeutics Drugs Players in Global Market, Ranking by Revenue (2021)

Table 3. Global Urological Cancer Therapeutics Drugs Revenue by Companies, (US\$, Mn), 2017-2022

Table 4. Global Urological Cancer Therapeutics Drugs Revenue Share by Companies, 2017-2022

Table 5. Global Urological Cancer Therapeutics Drugs Sales by Companies, (K MT), 2017-2022

Table 6. Global Urological Cancer Therapeutics Drugs Sales Share by Companies, 2017-2022

Table 7. Key Manufacturers Urological Cancer Therapeutics Drugs Price (2017-2022) & (USD/MT)

Table 8. Global Manufacturers Urological Cancer Therapeutics Drugs Product Type

Table 9. List of Global Tier 1 Urological Cancer Therapeutics Drugs Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Urological Cancer Therapeutics Drugs Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Global Urological Cancer Therapeutics Drugs Revenue (US\$, Mn), 2017-2022

Table 13. By Type - Global Urological Cancer Therapeutics Drugs Revenue (US\$, Mn), 2023-2028

Table 14. By Type - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2017-2022

Table 15. By Type - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2023-2028

Table 16. By Application – Global Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2021 & 2028

Table 17. By Application - Global Urological Cancer Therapeutics Drugs Revenue (US\$, Mn), 2017-2022

Table 18. By Application - Global Urological Cancer Therapeutics Drugs Revenue (US\$, Mn), 2023-2028

Table 19. By Application - Global Urological Cancer Therapeutics Drugs Sales (K MT),

2017-2022

Table 20. By Application - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2023-2028

Table 21. By Region – Global Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2021 VS 2028

Table 22. By Region - Global Urological Cancer Therapeutics Drugs Revenue (US\$, Mn), 2017-2022

Table 23. By Region - Global Urological Cancer Therapeutics Drugs Revenue (US\$, Mn), 2023-2028

Table 24. By Region - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2017-2022

Table 25. By Region - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2023-2028

Table 26. By Country - North America Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - North America Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - North America Urological Cancer Therapeutics Drugs Sales, (K MT), 2017-2022

Table 29. By Country - North America Urological Cancer Therapeutics Drugs Sales, (K MT), 2023-2028

Table 30. By Country - Europe Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2022

Table 31. By Country - Europe Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2023-2028

Table 32. By Country - Europe Urological Cancer Therapeutics Drugs Sales, (K MT), 2017-2022

Table 33. By Country - Europe Urological Cancer Therapeutics Drugs Sales, (K MT), 2023-2028

Table 34. By Region - Asia Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2022

Table 35. By Region - Asia Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2023-2028

Table 36. By Region - Asia Urological Cancer Therapeutics Drugs Sales, (K MT), 2017-2022

Table 37. By Region - Asia Urological Cancer Therapeutics Drugs Sales, (K MT), 2023-2028

Table 38. By Country - South America Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2022

Table 39. By Country - South America Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2023-2028

Table 40. By Country - South America Urological Cancer Therapeutics Drugs Sales, (K MT), 2017-2022

Table 41. By Country - South America Urological Cancer Therapeutics Drugs Sales, (K MT), 2023-2028

Table 42. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2022

Table 43. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2023-2028

Table 44. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Sales, (K MT), 2017-2022

Table 45. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Sales, (K MT), 2023-2028

Table 46. Novartis Corporate Summary

Table 47. Novartis Urological Cancer Therapeutics Drugs Product Offerings

Table 48. Novartis Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)

Table 49. Pfizer Corporate Summary

Table 50. Pfizer Urological Cancer Therapeutics Drugs Product Offerings

Table 51. Pfizer Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)

Table 52. Johnson & Johnson Corporate Summary

Table 53. Johnson & Johnson Urological Cancer Therapeutics Drugs Product Offerings

Table 54. Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)

Table 55. AstraZeneca Corporate Summary

Table 56. AstraZeneca Urological Cancer Therapeutics Drugs Product Offerings

Table 57. AstraZeneca Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)

Table 58. Astellas Corporate Summary

Table 59. Astellas Urological Cancer Therapeutics Drugs Product Offerings

Table 60. Astellas Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)

Table 61. Bristol-Myers Squibb Corporate Summary

Table 62. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product Offerings

Table 63. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)

Table 64. Abbott Laboratories Corporate Summary

Table 65. Abbott Laboratories Urological Cancer Therapeutics Drugs Product Offerings
Table 66. Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)
Table 67. Celgene Corporation Corporate Summary
Table 68. Celgene Corporation Urological Cancer Therapeutics Drugs Product Offerings
Table 69. Celgene Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)
Table 70. Dendreon Corporation Corporate Summary
Table 71. Dendreon Corporation Urological Cancer Therapeutics Drugs Product Offerings
Table 72. Dendreon Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)
Table 73. Ferring Pharmaceuticals Corporate Summary
Table 74. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product Offerings
Table 75. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)
Table 76. GlaxoSmithKline plc Corporate Summary
Table 77. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product Offerings
Table 78. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)
Table 79. Indevus Pharmaceuticals Inc Corporate Summary
Table 80. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product Offerings
Table 81. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)
Table 82. Ipsen Corporate Summary
Table 83. Ipsen Urological Cancer Therapeutics Drugs Product Offerings
Table 84. Ipsen Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)
Table 85. Roche Healthcare Corporate Summary
Table 86. Roche Healthcare Urological Cancer Therapeutics Drugs Product Offerings
Table 87. Roche Healthcare Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)
Table 88. Sanofi S.A. Corporate Summary
Table 89. Sanofi S.A. Urological Cancer Therapeutics Drugs Product Offerings
Table 90. Sanofi S.A. Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US\$, Mn) and Average Price (USD/MT) (2017-2022)
Table 91. Urological Cancer Therapeutics Drugs Production Capacity (K MT) of Key

Manufacturers in Global Market, 2020-2022 (K MT)

Table 92. Global Urological Cancer Therapeutics Drugs Capacity Market Share of Key Manufacturers, 2020-2022

Table 93. Global Urological Cancer Therapeutics Drugs Production by Region, 2017-2022 (K MT)

Table 94. Global Urological Cancer Therapeutics Drugs Production by Region, 2023-2028 (K MT)

Table 95. Urological Cancer Therapeutics Drugs Market Opportunities & Trends in Global Market

Table 96. Urological Cancer Therapeutics Drugs Market Drivers in Global Market

Table 97. Urological Cancer Therapeutics Drugs Market Restraints in Global Market

Table 98. Urological Cancer Therapeutics Drugs Raw Materials

Table 99. Urological Cancer Therapeutics Drugs Raw Materials Suppliers in Global Market

Table 100. Typical Urological Cancer Therapeutics Drugs Downstream

Table 101. Urological Cancer Therapeutics Drugs Downstream Clients in Global Market

Table 102. Urological Cancer Therapeutics Drugs Distributors and Sales Agents in Global Market

List Of Figures

LIST OF FIGURES

Figure 1. Urological Cancer Therapeutics Drugs Segment by Type

Figure 2. Urological Cancer Therapeutics Drugs Segment by Application

Figure 3. Global Urological Cancer Therapeutics Drugs Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Urological Cancer Therapeutics Drugs Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Urological Cancer Therapeutics Drugs Revenue, 2017-2028 (US\$, Mn)

Figure 7. Urological Cancer Therapeutics Drugs Sales in Global Market: 2017-2028 (K MT)

Figure 8. The Top 3 and 5 Players Market Share by Urological Cancer Therapeutics Drugs Revenue in 2021

Figure 9. By Type - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028

Figure 10. By Type - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028

Figure 11. By Type - Global Urological Cancer Therapeutics Drugs Price (USD/MT), 2017-2028

Figure 12. By Application - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028

Figure 13. By Application - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028

Figure 14. By Application - Global Urological Cancer Therapeutics Drugs Price (USD/MT), 2017-2028

Figure 15. By Region - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028

Figure 16. By Region - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028

Figure 17. By Country - North America Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028

Figure 18. By Country - North America Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028

Figure 19. US Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 20. Canada Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 21. Mexico Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn),

2017-2028

Figure 22. By Country - Europe Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028

Figure 23. By Country - Europe Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028

Figure 24. Germany Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 25. France Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 26. U.K. Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 27. Italy Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 28. Russia Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 29. Nordic Countries Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 30. Benelux Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 31. By Region - Asia Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028

Figure 32. By Region - Asia Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028

Figure 33. China Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 34. Japan Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 35. South Korea Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 36. Southeast Asia Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 37. India Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 38. By Country - South America Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028

Figure 39. By Country - South America Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028

Figure 40. Brazil Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 41. Argentina Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 42. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs

Revenue Market Share, 2017-2028

Figure 43. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028

Figure 44. Turkey Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 45. Israel Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 46. Saudi Arabia Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 47. UAE Urological Cancer Therapeutics Drugs Revenue, (US\$, Mn), 2017-2028

Figure 48. Global Urological Cancer Therapeutics Drugs Production Capacity (K MT), 2017-2028

Figure 49. The Percentage of Production Urological Cancer Therapeutics Drugs by Region, 2021 VS 2028

Figure 50. Urological Cancer Therapeutics Drugs Industry Value Chain

Figure 51. Marketing Channels

I would like to order

Product name: Urological Cancer Therapeutics Drugs Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/UA7249E3D025EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UA7249E3D025EN.html>